Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Bellerophon Therapeutics Stock Up 2.2 %
BLPH Stock traded up $0.03 during midday trading on Friday, reaching $1.42. The company had a trading volume of 10,040 shares, compared to its average volume of 20,722. The company has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.63. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $4.49.
Bellerophon Therapeutics (NASDAQ:BLPH - Get Rating) last announced its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities analysts anticipate that Bellerophon Therapeutics will post -2.31 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, StockNews.com started coverage on Bellerophon Therapeutics in a research note on Tuesday, August 9th. They issued a "sell" rating for the company.